EPO responsible for DR

Article

Erythropoietin (EPO) could be responsible for the development of diabetic retinopathy, according to a study published in the August 2008 issue of Eye.

Erythropoietin (EPO) could be responsible for the development of diabetic retinopathy, according to a study published in the August 2008 issue of Eye.

J. Garcì-Arumì of the Department of Ophthalmology, Hospital Vall d' Hebron, Universidad Autónoma de Barcelona, Spain and colleagues investigated the role of EPO in macular oedema-causing conditions - as subjects with diabetic macular oedema (DME) have high levels of EPO - by comparing vitreous EPO levels in subjects with macular oedema secondary to retinal vein occlusion (RVO) with the EPO levels of DME and control subjects.

The team found the median vitreous level of EPO in RVO subjects to be 76 mU/ml (range: 30–806); in control subjects, the median level was 25 mU/ml (range: 10–75); in DME subjects, the median level was 430 mU/ml (range: 41–3000).

As the levels of EPO were significantly higher in DME subjects than in RVO or control subjects, the team concluded that, while EPO may play a role in the development of diabetic retinopathy, it does not have a role in the pathogenesis of macular oedema secondary to RVO.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.